Kisspeptin receptor agonist; reproductive neuropeptide

Kisspeptin-10

aka KP-10 · KP10 · Kp10 · kisspeptin 112–121

Evidence grade
Grade C: Preliminary human data
for testosterone / libido support
User score everyone · n = 14
US FDA Not approved FDA safety-risk list (Category 2) · checked 2026-11-13
WADA 2026 Prohibited (S2.2.1) in males, at all times · checked 2026-11-13
EU No data · checked 2026-11-13

Goals: Cognition & mood · Libido & sexual health Compare with another peptide →

User reports

approximate — combined from two independent Reddit reads

Men 45–60

0 men aged 45–60

No reports in this group yet.

All men

8 men

small sample · n = 8

Outcome positive 6 of 8 · mixed 1 of 8 · no effect 1 of 8

Benefits libido 7 of 8 · other 6 of 8 · erection 5 of 8 · mood / anxiety 2 of 8

Side effects other 2 of 8 · insomnia 1 of 8 · low mood 1 of 8

Why stopped side effects 1 of 8

Stopped 1 of 8 Used with other compounds 2 of 8

Everyone

14 people

  • Positive: 10 of 14 (71%)
  • Mixed: 2 of 14 (14%)
  • No effect: 1 of 14 (7%)
  • Unclear: 1 of 14 (7%)
Benefits reported of 14
Benefits reported (n = 14)
ItemReports
Libido8 of 14 (57%)
Other7 of 14 (50%)
Erection5 of 14 (36%)
Mood / anxiety4 of 14 (29%)
Endurance1 of 14 (7%)
Energy1 of 14 (7%)
Focus / cognition1 of 14 (7%)
Side effects reported of 14
Side effects reported (n = 14)
ItemReports
Insomnia2 of 14 (14%)
Other2 of 14 (14%)
Low mood1 of 14 (7%)
Why people stopped of 14
Why people stopped (n = 14)
ItemReports
Side effects1 of 14 (7%)

Stopped 1 of 14 (7%) Used with other compounds 2 of 14 (14%)

User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds.

In their words

  • “I started sleeping terribly bad. 3-4 hours every night.”

  • “noticed an improvement in libido and EQ”

  • “Better libido and erections. Less refractory period.”

  • “After 3 Months of daily 100-150 micrograms Kisspeptin-10 I had huge problems with sleep, very heavy legs and was often on the brink of crying.”

  • “In the second week, that's when I noticed it - morning wood consistently, every day. I was surprised but thrilled with this.”

  • “I now take daily 100 microgramms Kisspeptin-10 since about 40 days. It helps me a lot with being able to have an orgasm.”

  • “Kisspeptin is upstream from LH/FSH and seems like a good idea, but it's half life is extremely short.”

Read summaries and method notes

Read 1. No man aged 45–60, but all three users were male. One took 100–150 mcg daily for about three months with clear sexual-symptom improvement, then developed severe insomnia, heavy legs and emotionality with a rise in estradiol and stopped (symptoms returned). A 21M on Wellbutrin and tadalafil reported better libido and erections in week one at 250 mcg daily; another man on testosterone said 250 mcg daily "works good". Kisspeptin-54 was not merged in.

Read 2. No man aged 45–60 (the only stated age was 30M). Men dominate (7 of 13), mostly PSSD and post-finasteride sufferers and TRT users: 5 positive, 1 mixed, 1 no practical effect (very short half-life vs HCG) — libido (6), erections/morning wood (4), genital sensitivity, orgasm or testicular volume (6). Everyone: 9 positive, 2 mixed, onset often within 1–14 days. At standard daily doses of 100–250 mcg: insomnia (2), an estradiol rise with heavy legs and crying spells leading to a stop, and a "crash" at 100–200 mcg controlled only by a big dose cut.

Note 1. No age-qualified 45-60 man. Two users were concurrently taking medications or testosterone that confound sexual and hormonal outcomes. Kisspeptin-54 reports were excluded.

Note 2. No 45-60 age among the 7 men. Linked threads from one OP were merged as one person. Kisspeptin-54 discussion and r/BodyHackGuide reports were excluded.

Each read counted people independently. Overlap between the two reads is estimated from shared threads and removed; counts are approximate. How we count.

Summary

Stimulates GnRH release and downstream LH/FSH, with testosterone increases in small physiology studies. Clinical treatment of low libido or hypogonadal symptoms has not been established; hormonal responses depend on dose and exposure pattern, so preserved natural production cannot be guaranteed.

Safety

  • Sparse chronic and reproductive safety evidence
  • FDA immunogenicity, impurity and characterization concerns
  • Hormonal response depends on dose and exposure pattern
  • No established safe self-injection regimen

From labels, regulators and trials. No signal in small studies ≠ safe.

Evidence C testosterone / libido support

C stands. Small physiology studies show LH and testosterone rise; no clinical outcome trial. The positive sexual-arousal RCTs used kisspeptin-54, a different peptide.

Human trials · 4

  1. PMID 216328072011Placebo-controlled dose-response physiology substudy 6 people

    Healthy men in the bolus substudy; separate infusion substudies had four men each

    Rapid LH stimulation; infusion experiments also increased testosterone and LH pulsatility. Source

  2. PMID 231532702013Small proof-of-concept endocrine experiments 12 people

    Five men with type 2 diabetes and biochemical hypogonadism plus seven healthy men; four diabetic men underwent infusion

    Infusion increased mean testosterone from 8.5 to 11.4 nmol/L, without demonstrating lasting symptom benefit. Source

  3. PMID 422304852026Uncontrolled within-subject 24-hour infusion experiment 3 people

    Healthy adult men

    LH rose then declined 13–47% from its peak while remaining elevated; no long-term therapeutic conclusion. Source

  4. PMID 425498272026Randomized single-blind placebo-controlled research program with small infusion substudies 15 people

    15 healthy men recruited across active substudies of 7, 4 and 7; publication also reports 12 controls, not a single parallel 15-person treatment trial

    Intermittent subcutaneous infusion sustained gonadotropin responses for 12 days; continuous exposure attenuated responses.

Bar length = trial size on a log scale.

Dose ranges

Reported ranges from labels and studies, with context. Not a recommendation.

  • clinical trial
    0.01–3 micrograms/kg intravenous boluses; 1.5–4 micrograms/kg/hour infusions in separate 2011 experiments Source
  • clinical trial
    12.5 micrograms/kg/hour intravenously for 24 hours in three men Source
  • clinical trial
    2026 research: 1.25–10 nmol/kg/hour subcutaneous acute infusions; 180 nmol/hour continuously for 5 days or 150 nmol/hour for 8 hours/day over 12 days in separate substudies Source on a non-primary host — not linked

Editorial ratings EDITORIAL

Editors’ judgement, 0–5. Opinion, not data; separate from grade and user score.

  • Safety 4 out of 5
  • Sleep 2.5 out of 5
  • Recovery not rated —
  • Cognitive not rated —

Sources

  1. pmc.ncbi.nlm.nih.gov/articles/PMC3380939/
  2. pubmed.ncbi.nlm.nih.gov/23153270/
  3. pmc.ncbi.nlm.nih.gov/articles/PMC13386888/
  4. fda.gov/media/94155/download
  5. wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
  6. ema.europa.eu/en/medicines
  7. pubmed.ncbi.nlm.nih.gov/21632807/
  8. pubmed.ncbi.nlm.nih.gov/42230485/
  9. pubmed.ncbi.nlm.nih.gov/42549827/
  10. pmc.ncbi.nlm.nih.gov/articles/PMC9898824/
  11. pubmed.ncbi.nlm.nih.gov/36287566/
  12. fda.gov/media/182089/download
  13. fda.gov/media/185412/download
  14. fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-pres
  15. fda.gov/advisory-committees/advisory-committee-calendar/october-29-2024-meeting-pharmacy-c
  16. fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-c

Reddit threads read · 12

1 further source on commercial or non-primary hosts not listed.

Research checked 2026-11-13.